UPDATE: Paced by Life Sciences and Diagnostics, Danaher's Q3 Revenues Grow 6 Percent | GenomeWeb

The story has been updated to include comments from Danaher's conference call this morning.

NEW YORK (GenomeWeb News) – Danaher's sales for the third quarter rose 6 percent year over year as its Life Sciences and Diagnostics segment grew almost 11 percent, the company reported today.

For the three months ended Sept. 27, the Washington-based conglomerate saw sales improve to $4.67 billion from $4.42 billion a year ago, edging out the consensus Wall Street estimate of $4.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.